Invasive Breast Carcinoma Recruiting Phase 2 Trials for Doxorubicin (DB00997)

Back to Invasive Breast Carcinoma

Also known as: Invasive carcinoma of breast / Breast cancer invasive NOS

IndicationStatusPhase
DBCOND0031787 (Invasive Breast Carcinoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02456857Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot InitiativeTreatment
NCT02957968Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast CaTreatment
NCT01750073Paclitaxel and Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Patients With Previously Untreated Breast CancerTreatment